PHA-408 is a potent, selective I kappa B-kinase 2 (IKK-2) inhibitor. PHA-408 is a tight binding, ATP competitive IKK-2 inhibitor with greater than 350-fold selectivity for IKK-2 vs IKK-1 (IC50 values of 10-40 nM at IKK-2 vs 14 µM at IKK-1). PHA-408 was shown to suppress inflammatory cellular events, and to reduce inflammation in animal models of arthritis.
Legal Information
Pfizer is a registered trademark of Pfizer, Inc.
Sold for research purposes under agreement from Pfizer Inc.
Other Notes
This compound was developed by Pfizer for Kinase Phosphatase Biology research. To learn more about Sigma′s partnership with Pfizer and view other authentic, high-quality Pfizer compounds, visit sigma.com/bsm-pfizer.